Athira Pharma to Participate in Upcoming June Conferences

Athira Pharma to Participate in Upcoming June Conferences

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in June.

Jefferies Healthcare Conference
Format: Fireside Chat
Date and Time: Wednesday, June 5, 2024, from 4:30 p.m. ET- 4:55 p.m. ET
Location: Marriott Marquis, New York City

Goldman Sachs 45 th Annual Healthcare Conference
Format: Fireside Chat
Date and Time: Wednesday, June 12, 2024, from 2:00 p.m. ET- 2:35 p.m. ET
Location: Loews Miami Beach Hotel, Miami

Live webcasts of the fireside chats can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-investor . An archived replay of the webcasts will be available for at least 30 days following the event.

About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of therapeutic candidates that modulate the neurotrophic HGF system, including fosgonimeton, which is being evaluated for the potential treatment of mild-to-moderate Alzheimer's disease in the Phase 2/3 LIFT-AD trial that is expected to report topline data in the second half of 2024. For more information, visit www.athira.com . You can also follow Athira on Facebook , LinkedIn and @athirapharma on X , formerly known as Twitter   , and Instagram .

Forward-Looking Statements
This communication contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding: product candidates as a potential treatment for Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, and other neurodegenerative diseases; future development plans; the anticipated reporting of data; expectations regarding the potential efficacy and commercial potential of Athira's product candidates; and Athira's ability to advance its product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "on track," "would," "expect," "plan," "believe," "intend," "pursue," "continue," "suggest," "potential," and similar expressions. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the data from preclinical and clinical trials may not support the safety, efficacy and tolerability of Athira's product candidates; development of product candidates may cease or be delayed; regulatory authorities could object to protocols, amendments and other submissions; future potential regulatory milestones for product candidates, including those related to current and planned clinical studies, may be insufficient to support regulatory submissions or approval; Athira may not be able to recruit sufficient patients for its clinical trials; the outcome of legal proceedings that have been or may in the future be instituted against Athira, its directors and officers; possible negative interactions of Athira's product candidates with other treatments; Athira's assumptions regarding its financial condition and the sufficiency of its cash, cash equivalents and investments to fund its planned operations may be incorrect; adverse conditions in the general domestic and global economic markets; the impact of competition; regulatory agencies may be delayed in reviewing, commenting on or approving any of Athira's clinical development plans as a result of pandemics or health epidemics, which could further delay development timelines; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks detailed in Athira's filings with the Securities and Exchange Commission from time to time. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.

Investor Contacts:
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ATHA
The Conversation (0)
SAGA Metals Completes Petrographic Analysis at Drill Ready Double Mer Uranium Project in Labrador, Canada

SAGA Metals Completes Petrographic Analysis at Drill Ready Double Mer Uranium Project in Labrador, Canada

Saga Metals Corp. ("SAGA" or the "Company") (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H) a North American exploration company focused on critical mineral discovery, is pleased to announce the completion of an initial petrographic petrological analysis, confirming the presence of uraninite, a key uranium mineral, hosted within the pegmatites identified along the 18km trend; verified through uranium count radiometrics and surface sampling at the Double Mer Uranium project in Labrador, Canada.

Saga Metals flagship Double Mer Uranium Project – Labrador, Canada

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
SAGA Metals Begins Mobilization Efforts for Maiden Drill Programs in Labrador, Canada

SAGA Metals Begins Mobilization Efforts for Maiden Drill Programs in Labrador, Canada

Saga Metals Corp. ("SAGA" or the "Company") (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H) a North American exploration company focused on critical mineral discovery, is pleased to announce the start of mobilization efforts for the Company's maiden drill programs at both of the 100% owned Double Mer Uranium and Radar Titanium-Vanadium (Ti-V) projects.

Michael Garagan, CGO & Director of Saga Metals Corp. comments: "The decision to run back-to-back drill programs and include the Radar Ti-V project is strategic and efficient as we are always looking to maximize our cost-effectiveness and shareholder value. We've engaged Gladiator Drilling out of Newfoundland; mobilization to the Double Mer Uranium project brings the contractors through southeastern Labrador and past the Radar project off route 516. Both the drilling and geological teams will be able to drive right into Radar's Hawkeye zone for an estimated 3-week drill program prior to initiating the Double Mer Uranium drill program. SAGA will be able to enter Q2 with drill results from two projects, setting the stage for a very active 2025 field season."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
SAGA Metals Provides Corporate Update and 2024 Year in Review

SAGA Metals Provides Corporate Update and 2024 Year in Review

Saga Metals Corp. ("SAGA" or the "Company") (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H) a North American exploration company focused on critical mineral discovery in North America, is pleased to provide a corporate update and review of key activities and achievements from 2024.

Key Corporate Highlights from 2024

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Completion of Indonesian Seaweed Joint Venture Transaction

Completion of Indonesian Seaweed Joint Venture Transaction

BPH Global (BP8:AU) has announced Completion of Indonesian Seaweed Joint Venture Transaction

Download the PDF here.

Invion Limited

Invion Doses First Patient in Phase I/II Non-Melanoma Skin Cancer Trial

Invion Limited (ASX: IVX) (“Invion” or the “Company”) is pleased to announce the dosing of the first patient in its Phase I/II non- melanoma skin cancer (NMSC) trial conducted at Veracity Clinical Research (Veracity) in Brisbane.

Keep reading...Show less
BPH Global

Seaweed Extraction of Critical Minerals R&D

BPH Global (BP8:AU) has announced Seaweed Extraction of Critical Minerals R&D

Download the PDF here.

Resonance Health Ltd

Resonance Contracted by Major Global Pharma Company for Clinical Drug Trial Worth $13.775 Million over 24 Months

Resonance Health Ltd (ASX: RHT) (Resonance or the Company) advises that it has been contracted by Sun Pharmaceutical Industries Limited, an international, publicly listed pharmaceutical company with global operations (Customer) to be the local Australian sponsor, and to provide clinical research organisation (CRO) services, trial site services, and imaging analysis services (collectively, Services), for their clinical trial in Australia of a new drug compound (Clinical Trial).

Keep reading...Show less

Latest Press Releases

Related News

×